28 results about "Drug elution" patented technology

Covered stents may be coated with or otherwise include a drug eluting composition. An illustrative stent may comprise an elongated tubular body having a strut framework defining a plurality of open cells. A polymeric coating may be disposed on a surface of the elongated tubular body and extending across the plurality of open cells and a first drug coating composition disposed on a surface of the polymeric coating.

An electronic system for multimodal diagnostic measurements and therapeutic interventions includes a plurality of element network layers vertically stacked one with another on a flexible substrate, each element network layer being bi-axially stretchable and comprising a plurality of elements configured in an addressable, interconnected array formed in a multilayered structure and operably performing a distinct function. The electronic system is a multimodal, multiplexed soft electronic system in a multilayered configuration that supports capabilities ranging from high-density spatiotemporal mapping of temperature, pressure and electrophysiological parameters, to options in programmable high-density actuation of thermal inputs and / or electrical stimulation, drug elution, radio frequency ablation, and / or irreversible electroporation ablation.

The disclosed concept includes the use of additive and / or subtractive manufacturing of mesoporous structures on two-dimensional sheets that are mechanically tunable, to provide a vascular graft that controls biodegradable graft host interactions, to improve graft patency and functionality long-term. The vascular graft includes the two-dimensional sheets in a rolled or tubular configuration to form a lumen wherein a surface and / or bulk modification is applied to the flat sheet. In addition, a plurality of mesoporous structures (e.g., gaps) are formed in the flat sheet using a subtractive manufacturing technique.

The present disclosure provides a method for preventing blood coagulation, comprising administering an effective amount of ginsenoside compound K (CK) to a subject in need thereof. The present disclosure also provides a use of ginsenoside compound K (CK) in the manufacture of a medicament for preventing blood coagulation. The present disclosure further provides a drug-eluting percutaneous coronary intervention (PCI) device comprising a vascular implant, the surface of which is coated with a first layer comprising ginsenoside compound K (CK) and a first bioabsorbable polymer, the first bioabsorbable polymer comprising poly-L-lactic acid (PLLA) and poly(L-lactide-co-ε-caprolactone) (PLCL) in a mass ratio of 60%-80%:20%-40%.

The application discloses a shock wave balloon catheter and belongs to the technical field of medical devices, which comprises a tube body, a balloon arranged on the outer wall of the tube body, at least one shock wave generator arranged in the balloon, and a convex device arranged on the outer surface of the balloon, wherein the convex device and the outer surface of the balloon are provided with a drug coating, at least one liquid injection cavity and a guide wire cavity are arranged in the tube body, and the liquid injection cavity is communicated with the balloon; the application integrates multi-form mechanical convex devices on the surface of the balloon, and coats anti-proliferation drugs on the surface of the convex device and the balloon, so that the trinity treatment of mechanical cutting / piercing, shock wave and drug elution is realized, the three functions of mechanical fragmentation of calcification / fibrosis lesions, shock wave deep lysis of calcified substances and local drug delivery are simultaneously achieved by the same instrument, one-time comprehensive treatment of complex vascular lesions is realized, and instrument replacement is avoided.

An aqueous humor outflow device comprises an arcuate scaffold that extends continuously in a circumferential direction from a first end to a second end of the aqueous humor outflow device and has a cross-sectional area that allows the arcuate scaffold to fit within a conventional aqueous humor outflow pathway of a mammalian eye. The arcuate scaffold comprises a docking station or a port within which to retain an implant device, such as a drug eluting device or a drug delivery device.

The invention relates to drug eluting shape memory foams. Tumorectomy is typically performed to prevent the progression of cancer. However, there is postoperative concern, including the formation of voids that may allow cancer cells to escape at the surgical site, which increases the risk of metastasis. To combat this challenge, embodiments include a polyurethane-based shape memory foam as a tissue void filling device, which can also release an anti-cancer drug. Such foams can be activated at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal tissue voids, and then act as a drug eluting device. Based on a pharmaceutical composition having polyvinyl alcohol (PVA), the characteristic of drug release from foam can be varied depending on application.

The application discloses a kind of preparation targeted therapeutic drug elution equipment, it is related to the field of drug preparation, the application includes base, electric control platform, screening groove, collection box, elution tank, water tank, drying groove, screening groove includes piston, piston is installed in the surface of screening groove body, collection box includes flap door, flap door is installed in the surface of screening groove body, elution tank includes motor, motor is installed in the other surface of elution tank body, water tank includes water pump, several water pumps are installed in water tank body inside, drying groove includes electric lifting plate, the other surface of water tank body is equipped with several sliding grooves, and the surface of electric lifting plate is slidably connected with the inside of sliding groove.The application is a kind of preparation targeted therapeutic drug elution equipment by setting screening groove, can be impurity treated to drug raw materials;By setting drying groove, the raw material after elution can be dried and dehydrated.

Systems and methods for treatment of vascular lesions. The system includes a drug-eluting distal portion of a drug-eluting catheter and a balloon of a balloon catheter configured for positioning with a vascular lesion. The method entails securing the drug-eluting distal portion to the inner wall of a blood vessel with the balloon, and delivery of therapeutic agents into the blood vessel wall while the drug-eluting distal portion is held against the wall of the blood vessel by the balloon. The distal infusion portion of the drug infusion catheter is first located within the lesion. After the drug infusion portion is in position, the balloon of the balloon catheter is translated into the lesion and inflated to press the drug-eluting portion into contact with the blood vessel wall and a therapeutic agent is delivered through the drug-eluting portion.

The present disclosure provides a method of preventing blood coagulation, comprising administering an effective amount of a ginsenoside Compound K (CK) to a subject in need. The present disclosure also provides use of a ginsenoside Compound K (CK) in the manufacture a medicament for preventing blood coagulation. Further, the present disclosure provides a drug-eluting percutaneous coronary intervention (PCI), comprising a blood vessel implant, wherein a surface of the blood vessel implant is coated with a first layer comprising ginsenoside Compound K (CK) and a first bioabsorbable polymer, wherein the first bioabsorbable polymer comprises Poly-L-lactic acid (PLLA) and Poly (L-Lactide-co-ε-Caprolactone) (PLCL) in a weight ratio of 60%-80%: 20%-40%.

A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.

A gastric retention system comprising one or more retention members comprising: at least one drug eluting component; and at least one laser joint component laser welded to the at least one drug eluting component.

Devices, systems, and methods for treating vascular defects are disclosed herein. According to some embodiments, the present technology includes an intravascular medical device comprising a tubular scaffold with a plurality of interconnected members. The tubular scaffold can be configured to expand from a collapsed state to an expanded state when implanted within a blood vessel. In some embodiments, the medical device further includes a plurality of carriers disposed about the tubular scaffold, each comprising a carrier body and a recess defined by the carrier body. A therapeutic agent may be released from the recesses in vivo, thereby providing a therapeutic effect to a treatment site.

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

A customizable inflatable bolster apparatus (100) may include a first leaf (102), a second leaf (104), or a balloon (108) disposed between the first leaf (102) and the second leaf (104) or on a single leaf. The balloon (108) may include an inflation port (110) and one or more tethers (112)(1)-(n)). The one or more tethers (112)(1)-(n)) may be disposed within the balloon (108) or around an external surface of the balloon (108). In response to the balloon (108) inflating, the one or more tethers ((112)(1)-(n)) may shape the balloon (108) into a desired shape. The apparatus (100) may apply a pressure to the tissue of patient and immobilize the tissue. The apparatus (100) may be applied to a skin graft, a patient's tissue, or a mucosa or fascia of the patient. The apparatus (100) may elute a substance, such as a pharmaceutical, into the tissue of the patient.

Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Medical devices and methods of making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. An occlusive medical device includes an expandable framework configured to transition between a first configuration and an expanded configuration; and a fabric disposed along at least a portion of the expandable frame. A drug eluting coating is disposed on the fabric, the drug eluting coating comprising a pharmaceutically active ingredient dispersed within a polymeric carrier.

The utility model provides a medicine elution device. The medicine elution device comprises a base and a cover body, the base comprises a first fixing main body and a groove formed in the first fixing main body; the cover body comprises a second fixed main body, a bulge, a liquid inlet channel and a liquid outlet channel; the liquid inlet channel and the liquid outlet channel are arranged in the second fixing body in parallel and are adjacent to the two sides of the protrusion respectively. When the first fixing main body is connected with the second fixing main body, the groove can accommodate the bulge; the difference between the curvature radius of the groove and the curvature radius of the bulge is equal to the depth of the arc-shaped space; the width of the bulge is smaller than that of the groove; the liquid inlet channel, the arc-shaped space and the liquid outlet channel are communicated in sequence to form a flowing channel of eluent. According to the drug elution device and the drug elution method, the drug release condition in the body can be accurately predicted, and the drug elution device and the drug elution method can serve as an effective means for quality control to provide guarantee for drug quality.

The current invention encompasses a steroid eluting biodegradable nasal implant. Aspects of the invention are drawn towards compositions of the nasal implant, methods of producing the steroid eluting biodegradable nasal implant, methods of use, and methods of treatment thereof.

A device for draining a cyst includes a catheter system configured to deploy an absorbent material, including but not limited to a foam, into a cyst. The absorbent material advantageously absorbs fluid contained within the cyst, e.g., fluid that can remain after aspiration, thereby reducing the likelihood of cyst recurrence. In various embodiments, the absorbent material can be bioabsorbable, radiolucent, echogenic, drug-eluting, or a combination thereof. In some embodiments, the device can also include or be coupled to a vacuum source that applies negative pressure to the cyst during foam delivery, thereby reducing the overall size and / or profile of the cyst.

An artificial lens capsule is provided for use during cataract surgery or in cases of aphakia (absence of lens) or posterior capsule rupture (PCR). A common complication during cataract surgery is the rupture of the posterior capsule, preventing the placement of a monofocal intraocular lens in the lens capsule due to inadequate support. Typically, a 3-piece, long haptic intraocular lens can be placed in the ciliary sulcus or capsule if the monofocal intraocular lens is sufficient. However, for placing a toric (astigmatism correcting) or presbyopia-correcting intraocular lens (multifocal), there are currently no options for a 3-piece sulcus-fixated lens. The artificial capsule disclosed herein can be inserted and supported by the anterior capsular rim or sutured into the sclera if capsular support is inadequate. This provides a stable region for placing a single-piece toric or presbyopia-correcting intraocular lens, thereby enhancing the options for lens placement in cases of inadequate capsular support. The device can also be a reservoir for other future intraocular and / or drug-eluting devices.

A sensor that can be implanted in a living animal (e.g., a human) and used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing and an analyte indicator covering at least a portion of the housing. The sensor may include a drug-delivery array covering at least a portion of the analyte indicator. The drug-delivery array may include one or more openings configured to allow the medium to pass through it and come into contact with the analyte indicator. The sensor may include one or more therapeutic agents. The therapeutic agents may reduce the degradation of the analyte indicator. The therapeutic agents may be incorporated within the drug-delivery array.

The invention discloses a leaching method for preparing a targeted therapeutic drug, which comprises the following steps: S1, adjusting CO2 to a critical temperature of 31.1 DEG C and a critical pressure of 7.38 MPa or above to a supercritical state, pre-leaching iodine-131 labeled carbon microspheres, then adding a surface modifier, and treating iodine-131 labeled carbon microsphere suspension with high-frequency ultrasonic waves; s2, transferring an iodine-131 labeled carbon microsphere suspension subjected to supercritical CO2 pre-leaching and surface treatment to a lead shielding centrifugal tube, adding 8-12mL of a leaching buffer solution into 1mL of carbon microspheres, performing vortex mixing, discarding supernate, and repeating twice; s3, enabling the carbon microsphere suspension to pass through an anion exchange column, flushing a resin column by using a leaching buffer solution, and collecting carbon microspheres in effluent; and S4, carrying out vortex mixing by using sterile injection water suspended carbon microspheres, discarding the supernate, repeating for three times, and enabling the suspension to pass through a sterile filter membrane. According to the method, the free iodine-131 in the iodine-131 carbon microspheres can be effectively removed, the medicine safety is guaranteed, and the potential harm to the thyroid gland of a patient is reduced.

Covered stents may be coated with or otherwise include a drug eluting composition. An illustrative stent may comprise an elongated tubular body having a strut framework defining a plurality of open cells. A polymeric coating may be disposed on a surface of the elongated tubular body and extending across the plurality of open cells and a first drug coating composition disposed on a surface of the polymeric coating.

Embodiments of the disclosure concern devices comprised of resorbable, shape-memory foam configured to allow for healing at a desired location. In particular embodiments, use of the device at the location utilizes the inherent environment at the location to allow expansion of the device, resulting in an improved fit for the device. In specific cases, the device is a vaginal stent configured for use for pediatric or adolescent populations.

The utility model discloses a medicament eluting coronary stent, which aims at solving the problem that the existing stent cannot be adjusted according to the diameter of a blood vessel when being used, and comprises a first arc-shaped stent, an arc-shaped adjusting frame, a limiting ball, an adjusting assembly and the like, the stent is expanded, and the arc-shaped adjusting frame slides in a second arc-shaped stent, so that the blood vessel can be conveniently and quickly eluted. When a limiting ball above the arc-shaped adjusting frame moves to the position of a through hole in the upper portion of the second arc-shaped support, the limiting ball is pushed out from the interior of the arc-shaped adjusting frame through a spring, the arc-shaped adjusting frame can be fixed into the second arc-shaped support, and when the blood vessel contracts to drive the limiting ball to contract towards the interior of the arc-shaped adjusting frame, the blood vessel can be fixed into the second arc-shaped support. The spring is driven to contract inwards through contraction of the limiting ball, so that the stent can contract and expand to a certain extent in the blood vessel, the blood vessel can be effectively protected against damage, proliferation of smooth muscles in the blood vessel cannot be stimulated, and thrombus in the blood vessel is effectively prevented.

A method of delivering a pharmaceutical composition to Schlemm's canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm's canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm's canal as it erodes.

Devices and methods for treating a target site in a body lumen are provided. A medical device includes a stent-like structure including a plurality of interlaced scribe filaments and non-scribe filaments. Generally, the stent-like structure may have more non-scribe filaments than the scribe filaments to provide greater structural support and concentrate scribe forces on only a small number of selected areas. The stent-like structure expands within the target site to score the target site and provide temporary structural support while infusing the target site with a therapeutic agent. Such therapeutic agent infusion occurs using a drug eluting or drug coating balloon disposed within a stent-like structure or by occluding a target site and introducing a drug into the occluded target site for residence for a period of time.